ReviewSkin health and disease2023
Proopiomelanocortin (POMC) and psychodermatology.
Review in Skin health and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Psychological Factors to Consider in Treating Patients with Acne Vulgaris.Journal of clinical medicine · 2026Review
- The Exposome in Melasma: A Comprehensive Review of Etiology, Mechanisms, and Implications for Management.Clinical, cosmetic and investigational dermatology · 2026Review
- Extracellular processing of proopiomelanocortin generates short beta endorphin that regulates rat keratinocytes via the delta opioid receptor.Scientific reports · 2025Article
- CD44 signaling in skin wound healing and regeneration.Journal of translational medicine · 2025Review
- Neuro-immuno-endocrinology of the skin: how environment regulates body homeostasis.Nature reviews. Endocrinology · 2025Review
- Exploring the Relationship Between Psychiatric Illness and Dermatological Disorders: A Narrative Review.Cureus · 2025Review
- Deep Learning-Based Drug Compounds Discovery for Gynecomastia.Biomedicines · 2025Article
- The Hormonal Background of Hair Loss in Non-Scarring Alopecias.Biomedicines · 2024Review
- Prevention of Melasma During Pregnancy: Risk Factors and Photoprotection-Focused Strategies.Clinical, cosmetic and investigational dermatology · 2024Review
- Proopiomelanocortin (POMC) and psychodermatology.Skin health and disease · 2023Review
- Psychodermatology special edition.Skin health and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychodermatology is the crossover discipline between Dermatology and Clinical Psychology and/or Psychiatry. It encompasses both Psychiatric diseases that present with cutaneous manifestations (such as delusional infestation) or more commonly, the psychiatric or psychological problems associated with skin disease, such as depression associated with psoriasis. These problems may be the result either of imbalance in or be the consequence of alteration in the homoeostatic endocrine mechanisms found in the systemic hypothalamic-pituitary-adrenal axis or in the local cutaneous corticotrophin-releasing factor-proopiomelanocortin-corticosteroid axis. Alteration in either of these systems can lead to immune disruption and worsening of immune dermatoses and vice-versa. These include diseases such as psoriasis, atopic eczema, acne, alopecia areata, vitiligo and melasma, all of which are known to be linked to stress. Similarly, stress and illnesses such as depression are linked with many immunodermatoses and may reflect alterations in the body's central and peripheral neuroendocrine stress pathways. It is important to consider issues pertaining to skin of colour, particularly with pigmentary disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.